Intellia Therapeutics Inc buy Canaccord Genuity Group Inc.
Start price
13.04.23
/
50%
€33.50
Target price
13.04.24
€59.72
Performance (%)
-29.85%
End price
14.04.24
€23.50
Summary
This prediction ended on 14.04.24 with a price of €23.50. The price of Intellia Therapeutics Inc has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -29.85%. Canaccord_Genuity_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Intellia Therapeutics Inc | -3.634% | -3.634% | -1.932% |
| iShares Core DAX® | 0.463% | -1.530% | 9.993% |
| iShares Nasdaq 100 | -1.792% | -5.385% | -0.879% |
| iShares Nikkei 225® | 5.124% | 8.053% | 30.035% |
| iShares S&P 500 | -1.760% | -3.821% | -0.209% |
Comments by Canaccord_Genuity_Gr for this prediction
In the thread Intellia Therapeutics Inc diskutieren
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "buy" rating and a $66.00 price target on the stock.
Ratings data for NTLA provided by MarketBeat
In the thread Trading Intellia Therapeutics Inc
Die von Canaccord_Genuity_Gr gewählte maximale Laufzeit wurde überschritten